BioMarin Pharmaceutical Inc.

Our Purpose

At BioMarin, we translate the promise of genetic discovery into medicines that make a profound impact on the life of each patient.

Since our founding in 1997, we’ve developed a proven track record of innovation with eight commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, we seek to unleash the full potential of genetic science by pursuing category-defining medicines that offer new possibilities for people living with genetically defined conditions around the world.

As we have looked to expand our impact, our approach to cutting-edge science has remained the same. We enlist the best of the best – people with the right technical expertise and a relentless drive to solve real problems – and create an environment that empowers our teams to pursue bold, innovative science.

  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2024highreshlpabestlogocert-lg.jpg
  • LI-top-companies-ireland-2024.jpg
770 Lindaro Street
San Rafael, CA 94901

105 Digital Drive
Novato, CA 94949
  • Featured Employer
NEWS
FDA
While the world has largely been focused on the development of vaccines and therapeutics for COVID-19, the U.S. FDA has remained busy lining up potential approvals of medications for other diseases and illnesses.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Scientific luminary and MacArthur Fellowship winner Kevin Eggan, Ph.D. will lead early-stage research at rare disease-focused BioMarin.
The agency indicated that they had completed the review cycle for the application but the application was not ready for approval in its current form.
With a busy August on the U.S. Food and Drug Administration’s schedule, this week is no exception. Here’s a look at some of what’s on the agency’s calendar.
BioMarin Pharmaceutical released new data today from its previously reported four-year update of the open-label Phase I/II study of valoctocogene roxaparvovec.
Check out this article for the impacts that Biotech Bay companies are experiencing due to COVID-19.
Biopharma and life sciences companies bolster their leadership teams and boards with this week’s Movers & Shakers.
The target action date is August 21, 2020.
JOBS
IN THE PRESS